Platinum-Sensitive Ovarian Cancer: Clinical Trials

4 recruiting, 2 completed, 1 active not recruiting, 1 not yet recruiting. 4 Phase 2, 2 Phase 3, 1 Early Phase 1, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	4	Recruiting 2, Active not recruiting 1, Not yet recruiting 1
Phase 3	2	Recruiting 2
Early Phase 1	1	Completed 1
Phase 1	1	Completed 1

Follow Platinum-Sensitive Ovarian Cancer: new trials by email Literature Review of Platinum-Sensitive Ovarian Cancer trials Research Report on Platinum-Sensitive Ovarian Cancer

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer Rina-S, Bevacizumab, Carboplatin - Platinum-Sensitive Ovarian Cancer, Ovarian Cancer	Phase 3	Recruiting	Genmab	688	2026-08-28	2026-10-07
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy Rina-S, Bevacizumab - Ovarian Cancer, Platinum-sensitive Ovarian Cancer	Phase 3	Recruiting	Genmab	544	2026-04-03	2026-10-06
Iparomlimab/Tuvonralimab + Standard Chemotherapy and Olaparib in Platinum-Sensitive Recurrent Ovarian Cancer Iparomlimab/Tuvonralimab - Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer	Phase 2	Not yet recruiting	The First Affiliated Hospital of Soochow University	45	2026-03-01	2026-03-06
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies IMGN151, Carboplatin, Bevacizumab - Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer	Phase 2	Recruiting	AbbVie	377	2025-07-30	2026-10-01
Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer AK112 low dose, Chemotherapy, Olaparib - Platinum-sensitive Ovarian Cancer	Phase 2	Recruiting	Akeso	150	2025-02-17	2025-04-16
Safety, Pharmacokinetics and Anti-tumor Activity of RP12146, in Patients With Solid Tumors RP12146 - Solid Tumor, Extensive-stage Small-cell Lung Cancer	Phase 1	Completed	Rhizen Pharmaceuticals SA	23	2021-10-05	2024-09-19
Variance of HRD From Paired Ovarian Cancer Ovarian Cancer, HRD		Unknown	Xiaoxiang Chen	50	2021-10-01	2021-10-06
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC OSE2101, Pembrolizumab 25 MG/ML [Keytruda] - Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer	Phase 2	Active not recruiting	ARCAGY/ GINECO GROUP	180	2021-08-05	2024-12-02
Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer Simvastatin 40mg - Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer	Early Phase 1	Completed	Marc Goodman	18	2021-01-25	2026-02-04

Narrower conditions

Ovarian Neoplasms (6)  ·  Breast Neoplasms (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Fallopian Tube Neoplasms (1)  ·  Neoplasms (1)  ·  Recurrence (1)  ·  Small Cell Lung Carcinoma (1)

Broader conditions

Neoplasms by Site (8)  ·  Adnexal Diseases (7)  ·  Female Urogenital Diseases (7)  ·  Female Urogenital Diseases and Pregnancy Complications (7)  ·  Genital Diseases (7)  ·  Genital Diseases, Female (7)  ·  Genital Neoplasms, Female (7)  ·  Neoplasms (7)  ·  Urogenital Diseases (7)  ·  Urogenital Neoplasms (7)  ·  Endocrine Gland Neoplasms (6)  ·  Endocrine System Diseases (6)  ·  Gonadal Disorders (6)  ·  Ovarian Diseases (6)  ·  Breast Diseases (1)

Interventions

Bevacizumab (3)  ·  Carboplatin (2)  ·  olaparib (2)  ·  1-dodecylpyridoxal (1)  ·  Drug Therapy (1)  ·  Gemcitabine (1)  ·  Paclitaxel (1)  ·  Simvastatin (1)  ·  pembrolizumab (1)

Sponsors

Genmab (2)  ·  ARCAGY/ GINECO GROUP (1)  ·  AbbVie (1)  ·  Akeso (1)  ·  Marc Goodman (1)  ·  Rhizen Pharmaceuticals SA (1)  ·  The First Affiliated Hospital of Soochow University (1)  ·  Xiaoxiang Chen (1)

Countries

United States (4)  ·  Japan (3)  ·  Belgium (2)  ·  China (2)  ·  France (2)  ·  Poland (2)  ·  Czechia (1)  ·  Finland (1)  ·  Germany (1)  ·  Israel (1)  ·  Norway (1)  ·  Spain (1)

Top investigators

Bobbie Jo Rimel, MD (1)  ·  Xiaoxiang Chen Chen, MD,PhD (1)

Results publications

PMID 39155847

NIH funding

2025 (2)